Medication info

Baltrio Tablet 10/160/20 milligrams

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
A dark pink, oval, double-convex film-coated tablet
Packaging
7 tablets/PTP
Approval status
Active

MFDS item code 202006711 · Approved 2020.09.29

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended that the tablet be taken at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking the amlodipine/valsartan combination together with rosuvastatin as separate products, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • risk factors for coronary heart disease
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • history of early coronary heart disease in the family
View approved original text

This medication is used for patients who need to take Amlodipine/Valsartan combination therapy and Rosuvastatin simultaneously. The Amlodipine/Valsartan combination is used in patients with essential hypertension for whom blood pressure is not well controlled with either Amlodipine or Valsartan alone. Rosuvastatin is an adjunctive therapy for dietary management in patients with hypercholesterolemia and dyslipidemia, especially effective in certain types such as familial hypercholesterolemia. In addition, Rosuvastatin lowers total cholesterol and LDL cholesterol, delays the progression of atherosclerosis, and reduces the risks of cardiovascular disease, stroke, and myocardial infarction. This medication is used to manage blood pressure and blood lipid levels together to improve overall cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended that the tablet be taken at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking the amlodipine/valsartan combination together with rosuvastatin as separate products, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. This medication is contraindicated for individuals with allergies to any of its components or for women who are pregnant or breastfeeding, patients with severe liver or kidney disease, and those with certain vascular and heart conditions. Patients with low sodium or fluid levels in the body may experience low blood pressure, so it is important to manage their condition before taking this medication and to carefully monitor blood pressure and condition during use. Patients with high potassium levels or those taking potassium-sparing diuretics should have their potassium levels checked frequently. Patients with compromised kidney function, kidney transplant recipients, and those with a history of angioedema require special caution when taking this medication, and it should be discontinued immediately if angioedema symptoms occur. Patients with heart failure or after myocardial infarction should periodically monitor kidney function and blood pressure changes, and be cautious of low blood pressure or exacerbation of cardiac symptoms during treatment. One of the ingredients in this medication, Rosuvastatin, may cause muscle-related side effects such as myalgia, myopathy, and rarely, rhabdomyolysis, so if muscle pain or weakness occurs, consult a doctor immediately. Additionally, liver function abnormalities or hepatitis symptoms may occur, so it is important to have regular liver function tests. This medication may cause dizziness or fatigue during driving or operating machinery, so caution is advised. There may be interactions with other medications, so if you are taking other medications, make sure to inform your healthcare provider. In elderly patients, the dosage should be adjusted appropriately, and physical reactions should be closely monitored. Women who are pregnant or breastfeeding should not take this medication, and if planning to become pregnant, suitable contraceptive methods should be used. This medication is not recommended for use in children and adolescents (under 18 years of age) as its safety and efficacy have not been established. In case of overdose, severe hypotension, shock, and cardiac abnormalities may occur, so care should be taken to not exceed the dosage, and if abnormal symptoms arise, immediate medical attention should be sought.

Side effects

Dizziness, abnormal perception, chest discomfort, chills, ALT increase, AST increase, weight gain, upper respiratory infection, myalgia, palpitations, ventricular extrasystole, diarrhea, duodenitis, gastritis, dyspnea, blepharospasm, eyelid edema, hypertriglyceridemia, benign prostatic hyperplasia, nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, drowsiness, orthostatic dizziness, sensory abnormalities, vertigo, tinnitus, tachycardia, heart palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, nausea, abdominal pain, constipation, thirst, rash, erythema, hyperhidrosis, rash, pruritus, joint swelling, low back pain, arthritis, muscle cramps, weakness, polyuria, nocturia, erectile dysfunction, edema, ankle swelling, facial swelling, peripheral edema, fatigue, flushing, asthenia, facial flushing, chest pain, pain, nocturnal enuresis, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, taste disturbances, peripheral neuropathy, hypertonicity, arrhythmia, bradycardia, atrial fibrillation, myocardial infarction, vasculitis, rhinitis, vomiting, dyspepsia, pancreatitis, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, dysuria, gynecomastia, pain, malaise, weight loss, weight gain, hemoglobin decrease, hematocrit decrease, neutropenia, serum sickness, increased serum potassium, vasculitis, elevated liver function tests, bullous dermatitis, renal failure, renal injury, increased serum creatinine, insomnia, reduced libido, pharyngitis, rhinitis, sinusitis, viral infection, angioedema, polyneuropathy, amnesia, peripheral neuropathy, thrombocytopenia, jaundice, transaminase increase, pruritus, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, headache, ALT increase, chest pain, cough, myalgia, CK increase, dizziness, constipation, AST increase, weakness, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, increased serum lithium concentration, elevated blood pressure, worsening hypertension, hemoptysis, productive cough, tonsillitis, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, oral hemorrhage, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood glucose, elevated triglycerides, insulin-dependent diabetes, diabetes complications, elevated blood pressure, worsening hypertension, neck/shoulder pain, leg fracture, toe fracture, spinal fracture, fracture, osteomyelitis, skin infection, unspecified dermatitis, skin mass, localized skin reaction, palpitations, second-degree atrioventricular block, worsening angina, auditory abnormalities, vestibulitis, overactive bladder, increased blood creatinine, retinal detachment, vitreous detachment, unspecified skin tumor-like condition, prostatic hyperplasia, herpes zoster, herniated disc, laceration

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius, which will ensure the efficacy of the medication.

Appearance and packaging

Appearance

A dark pink, oval, double-convex film-coated tablet

Package unit

7 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.